1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. World Health Organization Classification of Tumours.
2. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 2002;16(10):1959–1973.
3. Huret JL, Chomienne C. t(15;17)(q22;q21). Atlas Genet Cytogenet Oncol Haematol. April 1998. URL: http://AtlasGeneticsOncology.org/Anomalies/t1517ID1035.html
4. Brown NJM, Ramalho M, Pedersen EW, Moravcsik E, Solomon E, Grimwade D PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders? Front Biosci. 2009;14:684–1707.
5. Lo Coco F, Ammatuna E, Sanz MA. Current treatment of acute promyelocytic leukemia. Haematologica. 2007;92(3):289–291.